<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817633</url>
  </required_header>
  <id_info>
    <org_study_id>213348</org_study_id>
    <secondary_id>4020-01-001</secondary_id>
    <nct_id>NCT02817633</nct_id>
  </id_info>
  <brief_title>A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)</brief_title>
  <official_title>A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-T cell
      immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be
      conducted in 2 parts: with Part 1 consisting of dose escalation and Part 2 dose expansion.
      Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 as a single agent (Part
      1a); in combination with anti-programmed cell death protein-1 (PD-1) antibody, nivolumab
      (Part 1b); in combination with anti-PD-1 antibody, TSR-042 (Part 1c); in combination with
      TSR-042 and anti-lymphocyte-activation gene 3 (LAG-3) antibody, TSR-033 (Part 1d); in
      combination with TSR-042 in participants not previously treated with programmed death-ligand
      1 [PD-(L)1] (Part 1e) and in combination with docetaxel (Part 1f). Part 2 of the study will
      evaluate the antitumor activity of TSR-022, both as monotherapy and in combination with
      TSR-042 in participants with pre-specified tumor types.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2016</start_date>
  <completion_date type="Anticipated">September 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of participants achieving dose limiting toxicity (DLTs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants achieving DLTs will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with Serious adverse events (SAEs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with treatment-emergent adverse event (TEAE)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. TEAEs defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with TEAEs leading to death</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants with TEAEs leading to death will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with AEs leading to discontinuation</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants with AEs leading to discontinuation will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with immune-related adverse events (irAEs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants with irAEs will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with abnormal hematology parameters</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Blood samples will be collected to assess the following hematology parameters: hemoglobin, Mean corpuscular (MCV), white blood cell count (WBC count), platelets, mean platelet volume, differential WBC count and coagulation factors including International normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with abnormal clinical chemistry parameters</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Blood samples will be collected to assess the following chemistry parameters: sodium, potassium, calcium, magnesium, chloride, glucose, creatinine, urea or blood urea nitrogen (BUN), bicarbonate, amylase, bilirubin, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein, albumin, lactate dehydrogenase and lipase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with abnormal thyroid function</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Blood samples will be collected to assess the levels of thyroid-stimulating hormone (TSH); triiodothyronine (T3), or free triiodothyronine (FT3) and free thyroxine (FT4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with abnormal urine parameters</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Urine samples will be collected to evaluate specific gravity, leucocyte esterase, nitrite, blood, bilirubin, protein, glucose, ketones and urobilinogen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with abnormal vital signs</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Blood pressure, pulse rate, respiratory rate and temperature will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with abnormal electrocardiogram (ECG) findings</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Participants will be supine or in a semi-recumbent position and rested for approximately 2 minutes before ECGs are recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with abnormal physical examination</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Physical examinations including weight will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status scores</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Performance status will be assessed using the ECOG scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants receiving concomitant medications</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Concomitant medications will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR is defined as the proportion of participants achieving complete response (CR) or partial response (PR) as assessed by investigator per RECIST version 1.1 will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-TSR-022 antibodies</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Serum samples will be collected for the determination of anti-TSR-022 antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-TSR-042 antibodies</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Serum samples will be collected for the determination of anti-TSR-042 antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-TSR-033 antibodies</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Serum samples will be collected for the determination of anti-TSR-033 antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: ORR by RECIST version 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The proportion of participants achieving complete response (CR) or partial response (PR) as assessed by investigatory per RECIST version 1.1 will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: ORR by immune-related RECIST (irRECIST)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR by (irRECIST) will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Duration of response (DOR) by RECIST version 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of disease progression per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of response (DOR) by RECIST version 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of disease progression per RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Disease control rate (DCR) by RECIST version 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR is defined as the percentage of participants achieving CR, PR, or stable disease (SD) as assessed by the Investigator per RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Disease control rate (DCR) by irRECIST</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR is defined as the percentage of participants achieving CR, PR, or stable disease (SD) as assessed by the Investigator per irRECIST will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Disease control rate (DCR) by RECIST version 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR is defined as the percentage of participants achieving CR, PR, or stable disease (SD) as assessed by the Investigator per RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Disease control rate (DCR) by irRECIST</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR is defined as the percentage of participants achieving CR, PR, or stable disease (SD) as assessed by the Investigator per irRECIST will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Progression-free survival (PFS) by RECIST version 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from date of first dose to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Progression-free survival (PFS) by irRECIST</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from date of first dose to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per irRECIST will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Progression-free survival (PFS) by RECIST version 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from date of first dose to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Progression-free survival (PFS) by irRECIST</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from date of first dose to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per irRECIST will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS is defined as the time from date of first dose of study treatment to the date of death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS is defined as the time from date of first dose of study treatment to the date of death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Maximum plasma concentration (Cmax) of TSR-022 when administered as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose.</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Cmax of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Cmax of TSR-022 when administered in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Cmax of TSR-022 when administered in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: Cmax of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: Cmax of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Minimum plasma concentration (Cmin) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Cmin of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Cmin of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose.</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Cmin of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: Cmin of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy.</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: Cmin of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Area under the concentration × time curve from time 0 to infinity AUC (0-inf) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: AUC (0-inf) of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: AUC (0-inf) of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: AUC (0-inf) of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: AUC (0-inf) of in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: AUC (0-inf) of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC (0-inf) of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Area under the concentration × time curve at steady state (AUCss) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: AUCss of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: AUCss of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: AUCss of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: AUCss of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: AUCss of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUCss of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Maximum plasma concentration at steady state (Cmax,ss) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Cmax,ss of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Cmax,ss of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Cmax,ss of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e : Cmax,ss of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f : Cmax,ss of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax,ss of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Minimum plasma concentration at steady state (Cmin,ss) of TSR-022 022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Cmin,ss of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Cmin,ss of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples for determination of serum levels of TSR-022 in combination with TSR-042.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Cmin,ss of of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: Cmin,ss of of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: Cmin,ss of of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin,ss of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Area under the concentration time curve from time 0 to last assessment (AUC 0-last) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: AUC 0-last of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: AUC 0-last of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: AUC 0-last of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: AUC 0-last of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: AUC 0-last of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC 0-last of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Clearance (CL) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: CL of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: CL of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: CL of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e : CL of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: CL of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: CL of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Volume of distribution (Vz) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Vz of TSR-022 and in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Vz of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Vz of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e : Vz of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: Vz of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Vz of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Terminal half life (t½) TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: t½ of TSR-022 and in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: t½ TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: t½ TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: t½ TSR-022 in combination with TSR-042 in participants not previously treated with PD-(L)1</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: t½ of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: t½ of TSR-022</measure>
    <time_frame>Predose, 0.25, 0.5 hour post dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">369</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part 1a: TSR-022 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a (monotherapy dose escalation) will evaluate TSR-022 at ascending weight-based doses. TSR-022 will be administered intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1b: TSR-022 in combination with nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1b will receive nivolumab at the standard dose in combination with ascending doses of TSR-022. The starting dose of TSR-022 will be the Part 1a dose at which less than or equal to (&lt;=)1 of 6 participants experienced dose-limiting toxicity (DLTs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1c: TSR-022 in combination with TSR-042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1c will receive escalating doses of TSR-022 in combination with TSR-042.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1d: TSR-022 in combination with TSR-042 and TSR-033</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1d will initially evaluate TSR-022 and TSR-033, at ascending doses in combination with TSR-042 at a constant dose. At each dose escalation step, only 1 drug will be escalated, either TSR-022 or TSR-033.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1e: TSR-022 in combination with TSR-042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1e will evaluate TSR-022 in combination with TSR-042 in participants with select cancer types who have not received prior treatment with anti-PD-L1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1f: TSR-022 in combination with TSR-042 and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1f will evaluate the triple combination therapy of TSR-022, TSR-042 , and docetaxel, Q3W, for safety. The starting dose of docetaxel will be 75 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort A (Melanoma) (TSR-022 as monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced or metastatic melanoma will be enrolled in Cohort A and will receive treatment with TSR-022 at RP2D as monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort A (Melanoma) (TSR-022 with TSR-042)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced or metastatic melanoma will be enrolled in Cohort A and will receive treatment with TSR-022 at RP2D in combination with TSR-042.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer (TSR-022-monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced or metastatic Non-small cell lung cancer (NSCLC) will be enrolled in Cohort B and will receive treatment with TSR-022 at RP2D as monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer(TSR-022 with TSR-042)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced or metastatic NSCLC will be enrolled in Cohort B and will receive treatment with TSR-022 at RP2D in combination with TSR-042.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2:CohortC Colorectal cancer (TSR-022 as monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced/metastatic Colorectal cancer (CRC) will be enrolled in this arm and will receive treatment with TSR-022 at RP2D as monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2:CohortC Colorectal cancer (TSR-022 with TSR-042)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced/metastatic CRC will be enrolled in Cohort C and will receive treatment with TSR-022 at RP2D in combination with TSR-042.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort D (TIM-3 selected NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced or metastatic NSCLC having a positive TIM-3 expression will be enrolled in Cohort D. Participants will be administered TSR-022 at RP2D in combination with TSR-042.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSR-022</intervention_name>
    <description>TSR-022 is a humanized immunoglobulin 4 (IgG4) mAb.</description>
    <arm_group_label>Part 1a: TSR-022 monotherapy</arm_group_label>
    <arm_group_label>Part 1b: TSR-022 in combination with nivolumab</arm_group_label>
    <arm_group_label>Part 1c: TSR-022 in combination with TSR-042</arm_group_label>
    <arm_group_label>Part 1d: TSR-022 in combination with TSR-042 and TSR-033</arm_group_label>
    <arm_group_label>Part 1e: TSR-022 in combination with TSR-042</arm_group_label>
    <arm_group_label>Part 1f: TSR-022 in combination with TSR-042 and Docetaxel</arm_group_label>
    <arm_group_label>Part 2: Cohort A (Melanoma) (TSR-022 as monotherapy)</arm_group_label>
    <arm_group_label>Part 2: Cohort A (Melanoma) (TSR-022 with TSR-042)</arm_group_label>
    <arm_group_label>Part 2: Cohort D (TIM-3 selected NSCLC)</arm_group_label>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer (TSR-022-monotherapy)</arm_group_label>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer(TSR-022 with TSR-042)</arm_group_label>
    <arm_group_label>Part2:CohortC Colorectal cancer (TSR-022 as monotherapy)</arm_group_label>
    <arm_group_label>Part2:CohortC Colorectal cancer (TSR-022 with TSR-042)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is a humanized IgG4 monoclonal antibody.</description>
    <arm_group_label>Part 1b: TSR-022 in combination with nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSR-042</intervention_name>
    <description>TSR-042 is a humanized IgG4 monoclonal.</description>
    <arm_group_label>Part 1c: TSR-022 in combination with TSR-042</arm_group_label>
    <arm_group_label>Part 1d: TSR-022 in combination with TSR-042 and TSR-033</arm_group_label>
    <arm_group_label>Part 1e: TSR-022 in combination with TSR-042</arm_group_label>
    <arm_group_label>Part 1f: TSR-022 in combination with TSR-042 and Docetaxel</arm_group_label>
    <arm_group_label>Part 2: Cohort A (Melanoma) (TSR-022 with TSR-042)</arm_group_label>
    <arm_group_label>Part 2: Cohort D (TIM-3 selected NSCLC)</arm_group_label>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer (TSR-022-monotherapy)</arm_group_label>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer(TSR-022 with TSR-042)</arm_group_label>
    <arm_group_label>Part2:CohortC Colorectal cancer (TSR-022 with TSR-042)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSR-033</intervention_name>
    <description>TSR-033 is a humanized IgG4 monoclonal antibody.</description>
    <arm_group_label>Part 1d: TSR-022 in combination with TSR-042 and TSR-033</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel is a commercially available chemotherapeutic agent.</description>
    <arm_group_label>Part 1f: TSR-022 in combination with TSR-042 and Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Participant is at least 18 years of age.

          -  Female participants of childbearing potential must have a negative serum or urine
             pregnancy test within 72 hours prior to the date of the first dose of study medication
             or be of non-childbearing potential.

          -  Participant has adequate organ function.

        Inclusion Criteria for Participants in Part 1 and Part 2 Cohorts A, B, and C:

          -  Participant with advanced or metastatic solid tumor who meets the requirements for the
             part of the study/cohort he/she will participate in, as follows:

          -  Part 1: Participant with advanced or metastatic solid tumor and has disease
             progression after treatment with available therapies that are known to confer clinical
             benefit or who is intolerant to treatment (except for Part 1e, where special interest
             tumor types will be specified by the Sponsor).

          -  Part 1e:

          -  Advanced or metastatic melanoma participants who have not been previously treated with
             anti-PD-1, anti-PD-L1, or anti cytotoxic T lymphocyte-associated protein-(CTLA-4)
             therapies. Participant may be treatment naïve.

          -  Advanced or metastatic NSCLC participants who have not received anti-PD-1 or
             anti-PD-L1 therapies and have received &lt;=2 prior lines of treatment.

          -  Part 2: Histologically proven advanced (unresectable) or metastatic solid tumor that
             is measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per
             RECIST version 1.1 criteria and meets 1 of the following disease types:

          -  Cohort A (melanoma) - Participants with advanced or metastatic melanoma who have
             progressed following treatment with an anti-PD-1 or anti-PD-L1 antibody.

          -  Cohort B (NSCLC) - Participants with advanced or metastatic NSCLC who have progressed
             following:

          -  Treatment with an anti-PD-1 or anti-PD-L1 antibody.

          -  Cohort C (CRC) - Participants with advanced/metastatic CRC who have progressed
             following standard treatment which must include fluoropyrimidine, oxaliplatin, and
             irinotecan, unless contraindicated. Participants should have received no more than 3
             prior lines of therapy (including adjuvant therapy).

          -  Biopsies

          -  Part 1: Participants must have archival tumor tissue available that is formalin-fixed
             and paraffin-embedded. Tumor tissue must be requested from off-site locations and
             confirmed available prior to dosing.

          -  For participants in Part 1 who do not have archival tissue, a new biopsy must be
             performed to obtain tumor tissue.

          -  Part 2 Cohorts A, B, and C: All participants enrolled in Part 2 Cohorts A to C are
             required to have fresh tumor tissue biopsy prior to dosing. Archival tissue should
             also be provided (if available) to enable a longitudinal analysis of tumor biomarkers.

          -  If a participants has had a biopsy prior to entering the 21-day screening period and
             within approximately 12 weeks of study treatment, that biopsy may be accepted as the
             Baseline fresh biopsy.

          -  All participants are also required to have lesions amenable to biopsy and to agree to
             tumor biopsies prior to the initiation of treatment (as noted above) approximately 4
             to 6 weeks after initiating treatment, and, if possible, upon treatment
             discontinuation (for participant with PD).

          -  Inclusion Criteria for Participants in Part 2 Cohort D

          -  Participants with advanced or metastatic NSCLC that is measurable by CT or MRI per
             RECIST version 1.1 criteria and meet the following criteria:

          -  NSCLC histology includes squamous or non-squamous cell carcinoma.

          -  Participants have received no more than 2 prior lines of therapy, which must include a
             platinum-based chemotherapy (eg, cisplatin, carboplatin) and an anti-PD-(L)1 antibody.

          -  Participants must have documented radiographic progression by RECIST version 1.1
             criteria on prior anti-PD-1 or anti-PD-L1 therapy.

          -  Biopsies

          -  If a participant has had a biopsy prior to entering the 35-day screening period and
             within approximately 12 weeks of study treatment, that biopsy may be accepted as the
             Baseline fresh biopsy.

        Exclusion Criteria

          -  History of Grade &gt;=3 immune-related AE with prior immunotherapy, with the exception of
             non-clinically significant lab abnormalities.

          -  Participant has known uncontrolled central nervous system (CNS) metastases and/or
             carcinomatous meningitis.

          -  Participant has a known additional malignancy that progressed or required active
             treatment within the last 2 years. Participants with a prior or concurrent malignancy
             whose natural history or treatment does not have the potential to interfere with the
             safety or efficacy assessment of the investigational regimen may be included only
             after discussion with the Medical Monitor.

          -  Participant is considered a poor medical risk due to a serious, uncontrolled medical
             disorder, nonmalignant systemic disease or active infection requiring systemic
             therapy.

          -  Participant is pregnant or breastfeeding, or expecting to conceive children within the
             projected duration of the study, starting with the Screening Visit through 150 days
             after the last dose of study treatment.

          -  Participant has a diagnosis of immunodeficiency or is receiving systemic steroid
             therapy or any other form of immunosuppressive therapy within 7 days prior to the
             first dose of study treatment.

          -  Participant has a known history of human immunodeficiency virus (HIV) infection or HIV
             1/2 antibodies.

          -  Participant has known active hepatitis B (eg, hepatitis B surface antigen [HBsAg]
             reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [HCV RNA]
             [qualitative] is detected).

          -  Participant has an active autoimmune disease that has required systemic treatment (ie,
             with use of disease-modifying agents, corticosteroids or immunosuppressive drugs).

          -  Participant has a history of pneumonitis.

          -  Participant has not recovered (ie, to Grade &lt;=1 or to Baseline) from radiation- and
             chemotherapy-induced AEs, has received transfusion of blood products (including
             platelets or red blood cells), or has received administration of colony-stimulating
             factors (including granulocyte-colony stimulating factor [G-CSF], granulocyte
             macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 3
             weeks prior to the first dose of study drug.

          -  Participant is currently participating and receiving study therapy or has participated
             in a study of an investigational agent and received investigational therapy or used an
             investigational device within 4 weeks prior to the first dose of study drug.

          -  Participant has received prior anticancer therapy (chemotherapy, targeted therapies,
             radiotherapy, or immunotherapy) within 21 days, or less than 5 times the half-life of
             the most recent therapy prior to study Day 1, whichever is shorter.

          -  Participant has not recovered adequately (Grade &lt;=1) from AEs and/or complications
             from any major surgery prior to starting therapy.

          -  Participant has received a vaccine within 7 days of planned start of study therapy.

          -  Participant has a known hypersensitivity to TSR-022 components or excipients, or, if
             applicable, nivolumab, TSR-042, or TSR-033 components or excipients.

        Exclusion Criteria for Participants in Part 1 and Part 2 Cohorts A, B, and C

          -  Participant received prior therapy as defined below:

          -  Part 1a: Anti-CTLA-4, anti-PD-1, anti-PD-1-ligand-1 (anti-PD-L1), or anti-PD-1
             ligand-2 (anti-PD-L2) agent within 3 weeks (that is, 21 days) prior to initiation of
             study treatment.

          -  Part 1b, Part 1c, Part 1d, and Part1f: Anti-CTLA-4 within 3 weeks (that is, 21 days)
             prior to initiation of study treatment and/or prior treatment with anti-PD-1,
             anti-PD-L1, anti-PD-L2, anti-TIM-3, or anti-LAG-3, or docetaxel agent that resulted in
             permanent discontinuation due to an AE.

          -  Part 1e: Prior treatment with with an anti-PD-(L)1, anti-LAG-3 or anti-TIM-3.

          -  NSCLC participants with known EGFR mutations, ALK translocations, or ROS1 mutations.

          -  Participants with uveal melanoma.

          -  Part 1f: History of severe hypersensitivity reaction to docetaxel, paclitaxel, or
             other drugs formulated with polysorbate 80.

          -  Part 2 Cohorts A, B, and C combination arms (TSR-022 + TSR-042):

          -  Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent that resulted in
             permanent discontinuation due to an AE.

          -  Prior treatment with an anti-LAG-3 or anti-TIM-3.

        Exclusion Criteria for Participants in Part 2 Cohort D

          -  A participant with negative (as determined by Central Testing Lab) or unevaluable
             TIM-3 expression from tissue obtained prior to study entry will not be eligible for
             the study.

          -  Participant has received prior therapy as defined below:

          -  Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent that resulted in
             permanent discontinuation due to an AE.

          -  Prior treatment with an anti-LAG-3 or anti-TIM-3.

          -  Radiologic or clinical progression &lt;= 8 weeks after initiation of prior anti-PD-1 or
             anti-PD-L1 antibody.

          -  Participants with known EGFR mutation, ALK translocation, or ROS1 mutation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Cente</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mahesh Seetharam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vivek Khemka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Edward F McClay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Abdul Mustajeeb Haseeb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Antoni Ribas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter D Boasberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Edward F McClay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Merrill K Shum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allen L. Cohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Karl Lewis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Falchook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia M Lorusso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chul Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Judy S Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zeynep Eroglu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ragini Kudchadkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard S Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60604-1104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allen L. Cohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hedy Kindler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard S Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammed Milhem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pikeville</city>
        <state>Kentucky</state>
        <zip>41501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher C. Croot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>John M Wallmark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Justin Gainor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Gutierrez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sardar Imam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjay Goel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-4744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anna C Pavlick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Bajor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Fiorillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Diwakar Davar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Theodore G Gourdin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Erika Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jason M. Melear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos R Becerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Richey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Julio Peguero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Yap</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Donald A. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503-1298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Habib M. H. Ghaddar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Donald A. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weslaco</city>
        <state>Texas</state>
        <zip>78596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Habib M. H. Ghaddar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander I. Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ying Zhuo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nataliya Uboha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <state>Navarra</state>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eduardo Castañón Álvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Moreno García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Valentina Boni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Manuel Trigo Pérez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eduardo Castañón Álvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Desamparados Roda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibodies</keyword>
  <keyword>TSR-022</keyword>
  <keyword>Cobolimab</keyword>
  <keyword>Advanced solid tumors</keyword>
  <keyword>Metastatic solid tumors</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>PD-1</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Anti-LAG-3</keyword>
  <keyword>TSR-033</keyword>
  <keyword>TSR-042</keyword>
  <keyword>Dostarlimab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

